{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:01:03Z","timestamp":1793818863787,"version":"4.6.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced cervical cancer (aCC) is associated with a poor prognosis for patients. While immune checkpoint inhibitors (ICIs) have demonstrated potential therapeutic benefits, their effectiveness can be hindered by inherent resistance mechanisms and the onset of immune-related adverse events (irAEs). The strategy of combining ICIs with anti-angiogenic agents has gained traction as a potentially effective treatment approach. Nonetheless, there is a notable absence of robust, systematic evidence to confirm the efficacy and safety of this combination specifically for aCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a thorough search of relevant studies across multiple databases, including PubMed, Embase, Cochrane Library, Web of Science, and Scopus. We extracted key outcome measures, such as overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) for further analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included three randomized controlled trials (RCTs;all evaluating first-line treatment for persistent, recurrent, or metastatic cervical cancer) and eight single-arm trials(predominantly later-line or mixed-line settings), encompassing a total of 1, 491 patients. The meta-analysis revealed that in RCTs, ICIs significantly improved OS, decreasing the risk of death by 16% (hazard ratio [HR] = 0.84, 95% confidence interval [CI]:0.78-0.91, P &amp;lt;0.001), and enhanced PFS, reducing the risk of disease progression by 18% (HR\u00a0=\u00a00.82, 95% CI:0.77-0.88, P &amp;lt;0.001). The combination group exhibited a higher objective response rate (ORR, risk ratio [RR] = 1.19, 95% CI:1.10-1.30, P &amp;lt;0.001) compared to the control group. Findings from single-arm studies provided supportive exploratory evidence, showing a pooled ORR of 0.57 (95% CI: 0.46-0.68).Safety profiles were generally acceptable in RCTs, but the absolute rate of severe toxicity in single\u2212arm studies was substantial (51% grade \u22653).Sensitivity analyses affirmed the robustness of the OS results (I\u00b2 = 0%), with a stable ORR despite observed heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pooled analysis of first-line RCTs indicates that combining ICIs with anti-angiogenic agents and chemotherapy demonstrates promising efficacy and a manageable safety profile in persistent, recurrent, or metastatic cervical cancer. However, vigilant monitoring and prompt management of immune therapy-related adverse events are crucial for patient safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , identifier CRD420251050867.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1747768","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:08Z","timestamp":1779342188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Dezhi","family":"Zhang","sequence":"first","affiliation":[{"name":"Pharmaceutical College, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Meng","sequence":"additional","affiliation":[{"name":"Pharmaceutical College, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Dong","sequence":"additional","affiliation":[{"name":"Pharmaceutical College, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Huang","sequence":"additional","affiliation":[{"name":"Pharmaceutical College, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Ding","sequence":"additional","affiliation":[{"name":"Pharmaceutical College, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmin","family":"Wu","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Fangchenggang","place":["Fangchenggang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Gao","sequence":"additional","affiliation":[{"name":"Guangxi Medical University Cancer Hospital","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chang","sequence":"additional","affiliation":[{"name":"Guangxi Medical University Cancer Hospital","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyi","family":"Ou","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dong","sequence":"additional","affiliation":[{"name":"Pharmaceutical College, Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e65","article-title":"Evolving standards and future directions for systemic therapies in cervical cancer","volume":"35","author":"Ang","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cac2.12629","article-title":"Advances in cervical cancer: current insights and future directions","volume":"45","author":"Xu","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.07.001","article-title":"Tumor vasculatures: A new target for cancer immunotherapy","volume":"40","author":"Liu","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00914","article-title":"First-line pembrolizumab + Chemotherapy versus placebo + Chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005092","article-title":"Imaging endpoints for clinical trial use: a RECIST perspective","volume":"10","author":"Liti\u00e8re","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.195","article-title":"RECIST - learning from the past to build the future","volume":"14","author":"Liti\u00e8re","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11576","article-title":"The use of and adherence to CTCAE v3.0 in cancer clinical trial publications","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jclinepi.2023.06.015","article-title":"Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review","volume":"161","author":"Crocker","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13643-019-1070-0","article-title":"Introducing RAPTOR: RevMan parsing tool for reviewers","volume":"8","author":"Schmidt","year":"2019","journal-title":"Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.1038\/s41467-022-35133-4","article-title":"A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma","volume":"13","author":"Xia","year":"2022","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100572","article-title":"100P Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: Updated efficacy and safety results","volume":"20","author":"Zhu","year":"2023","journal-title":"Immuno Oncol Technol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.5540","article-title":"Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study)","volume":"42","author":"Tse","year":"2024","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.5530","article-title":"A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer","volume":"42","author":"Guo","year":"2024","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.e17506","article-title":"Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12547","article-title":"Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study","volume":"44","author":"Lan","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e44","article-title":"Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214)","volume":"36","author":"Li","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070115","article-title":"Human papillomavirus vaccination and cervical cancer risk","volume":"379","author":"Rahangdale","year":"2022","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-473702","article-title":"Challenges and opportunities for global cervical cancer elimination: how can we build a model for other cancers","volume":"45","author":"Adebamowo","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-473114","article-title":"State of the art: therapies now and around the corner for gynecologic cancers","volume":"45","author":"Moore","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.12.003","article-title":"Antiangiogenic therapy: creating a unique \"window\" of opportunity","volume":"6","author":"Lin","year":"2004","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-2025","article-title":"Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia","volume":"71","author":"Matsumoto","year":"2011","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/28412","article-title":"Combined effects of angiostatin and ionizing radiation in antitumour therapy","volume":"394","author":"Mauceri","year":"1998","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ccell.2022.12.006","article-title":"Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop","volume":"41","author":"Hua","year":"2023","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-021-09792-8","article-title":"High endothelial venules (HEVs) in immunity, inflammation and cancer","volume":"24","author":"Blanchard","year":"2021","journal-title":"Angiogenesis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01463-9","article-title":"Advances in the management of recurrent cervical cancer: state of the art and future perspectives","volume":"25","author":"Giudice","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/life14030344","article-title":"Immunotherapy in cervical and endometrial cancer: current landscape and future directions","volume":"14","author":"Stefanoudakis","year":"2024","journal-title":"Life (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1615\/critrevtherdrugcarriersyst.2025044498","article-title":"Immunotherapy in cervical cancer: an evolutionary paradigm in women's reproductive health","volume":"42","author":"Damani","year":"2025","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154458","article-title":"New frontiers in locally advanced cervical cancer treatment","volume":"13","author":"Massobrio","year":"2024","journal-title":"J Clin Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2323596","article-title":"Targeting cervical cancer with anti-PD-1 antibodies: what is new","volume":"24","author":"Greenman","year":"2024","journal-title":"Expert Opin Biol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1747768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:09Z","timestamp":1779342189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1747768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1747768"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1747768","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1747768"}}